Abstract of the 38th annual meeting of the European Association for the study of the liver| Volume 38, SUPPLEMENT 2, 18-19, April 2003

Efficacy of peginterferon ALFA-2A (40KD) (PEGASYS) plud ribavirin for 24 weeks in genotype 1 patients with chronic hepatitis C followed by mono or combination therapy for 22 weeks: Preliminary analysis of an open, multicenter, randomized trial

      This paper is only available as a PDF. To read, Please Download here.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect